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Abstract: A family of compounds with the general formula [Fe(η5-C5H5)(CO)(PPh3)(NCR)]+ has been
synthesized (NCR = benzonitrile (1); 4-hydroxybenzonitrile (2); 4-hydroxymethylbenzonitrile (3);
4-aminobenzonitrile (4); 4-bromobenzonitrile (5); and, 4-chlorocinnamonitrile (6)). All of the
compounds were obtained in good yields and were completely characterized by standard spectroscopic
and analytical techniques. Compounds 1, 4, and 5 crystallize in the monoclinc P21/c space group and
packing is determined by short contacts between the phosphane phenyl rings and cyclopentadienyl
(compounds 1 and 4) or pi-pi lateral interactions between the benzonitrile molecules (complex 5).
DFT and TD-DFT calculations were performed to help in the interpretation of the experimental
UV-Vis. data and assign the electronic transitions. Cytotoxicity studies in MDA-MB-231 breast and
SW480 colorectal cancer-derived cell lines showed IC50 values at a low micromolar range for all
of the compounds in both cell lines. The determination of the selectivity index for colorectal cells
(SW480 vs. NCM460, a normal colon-derived cell line) indicates that the compounds have some
inherent selectivity. Further studies on the SW480 cell line demonstrated that the compounds induce
cell death by apoptosis, inhibit proliferation by inhibiting the formation of colonies, and affect the
actin-cytoskeleton of the cells. These results are not observed for the hydroxylated compounds 2
and 3, where an alternative mode of action might be present. Overall, the results indicate that the
substituent at the nitrile-based ligand is associated to the biological activity of the compounds.
Keywords: iron(II)-cyclopentadienyl; nitrile-based ligands; colorectal cancer; triple negative
breast cancer
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1. Introduction
Cancer is among one of the deadliest diseases worldwide. Most of the chemotherapeutic agents
that are used to treat this illness are organic molecules, yet, the success of transition metal complexes
for cancer treatments is well demonstrated by the clinical use of platinum-based agents and the
presence of several metal-based compounds in clinical trials [1]. Despite such successes, the lack of
selectivity and multidrug resistance of such metallodrugs constitutes a serious challenge to overcome.
In that frame, the use of biologically essential metals, such as iron, seems to be a valuable strategy [2].
The better-known example is the ferrocifen family of compounds, ferrocenyl analogues of tamoxifen,
developed by Jaouen and coworkers [2–8]. Tamoxifen is the first line chemotherapeutic for patients
with hormone-dependent breast cancer (oestrogen receptor α-positive, ERα+). The replacement of a
phenyl group in tamoxifen by a ferrocenyl group originated compounds that are highly active against
both ERα+ and hormone-independent (ERα−) breast cancer cells (Figure 1a). Although this was an
outstanding result, the ferrocifen-based compounds suffer from poor bioavailability, considerably
delaying their entrance into clinical trials. Several formulations are being tested in order to overcome
this limitation, such as nanoparticles or lipid nanocapsules [5,9].
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Figure 1. Organometallic iron-based compounds with potential as anticancer agents. (a) Ferrocifen;
(b) L = imidazole or nitrile based ligand; (c) L = Cl, Br, I, isothiocyanates; (d) PR3 = phosphane-based
ligand; and, (e) R = Me, xyl, CH2Ph; R′ = Ph, 2-naphthyl, 3-C6H4OH, 4-C6H4CO2H, 3-thiophenyl, Me,
CO2Me, 2-pyridyl; R” = H, CO2Me, Me, Ph.
We have been exploring the use of half-sandwich ruthenium(II)-cyclopentadienyl-based
compounds as prospective anticancer agents [10]. Recently, we have successfully dedicated our
studies to cancers without clinical cure, such as triple negative breast cancer (TNBC) [11–16] and
colorectal cancer (CRC) with KRAS or BRAF mutations [17]. Given the promising results that
were obtained with ruthenium, and since iron belongs to the same Group of the Periodic Table,
being more abundant and cheaper, the exploitation of iron(II)-cyclopentadienyl-based compounds
merits being explored. Our preliminary results on the [Fe(η5-Cp)(dppe)(L)]+ compounds, where
L is an imidazole [18], a quinolinecarbonitrile [19], or a pyrazinecarbonitrile [19]-based ligand
(Figure 1b), have validated the strategy. Later works by us [20], Fan et al., [21], and Dyson, Marchetti
et al., [22] on {Fe(Cp)(CO)n} or {Fe2(Cp)2(CO)2} based-compounds showed that the replacement of
dppe by monodentate ligands allows for the synthesis of stable and more water soluble complexes
(Figure 1c–e). In particular, we have explored different substituents on the phosphane ligands of
[Fe(η5-Cp)(CO)(phosphane)(aminobenzonitrile)]+ compounds, concluding that triphenylphosphane
was the ligand that imparted a better cytotoxic profile to the compounds on human cervical cancer cells
(HeLa) [20]. On the continuation of this structure-activity work, our strategy of molecular design has
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now included structural changes on the nitrile-based ligand. Thus, a series of five benzonitriles with
different substituents at the para position (H, OH, CH2OH, NH2, and Br) were used, as well as a longer
aromatic system (4-chlorocinnamonitrile). The influence of the nitriles on the complexes’ activity was
assessed in two different cancer cell lines (breast and colorectal). The results revealed that the activity
of the compounds is dependent on these structural changes.
2. Results and Discussion
2.1. Synthesis
The new cationic complexes of the general formula [Fe(η5-C5H5)(CO)(PPh3)(NCR)]+ were
obtained by iodide abstraction while using AgCF3SO3 followed by reaction with nitriles (NCR
= benzonitrile (1); 4-hydroxybenzonitrile (2); 4-hydroxymethylbenzonitrile (3); 4-aminobenzonitrile
(4); 4-bromobenzonitrile (5); 4-chlorocinnamonitrile (6)) and, in acetone at room temperature for
24 h (Scheme 1). Pure compounds were obtained in 65–79% yields, by column chromatography in
neutral alumina, while using a mixture of acetone/n-hexane as eluent system for all complexes (cf
experimental section).
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Scheme 1. Reaction scheme for the synthesis of the starting material. [Fe(η5-C5H5)(CO)(PPh3)I] and
for compounds 1–6. Numbering of the ligands is for NMR purposes.
2.2. NMR Spectroscopy
NMR characterization of the aforementioned complexes was done by 1H, 13C{1H}-apt, 31P{1H},
HMQC, and HMBC. Table 1 presents the 1H NMR values of the Cp ligand and of the ortho protons of
each benzonitrile (H3). As it can be observed, there is a deshielding on the Cp upon the coordination of
the nitriles up to 0.64 ppm, as expected for ‘FeCp’ cationic complexes. Additionally, since benzonitriles
are good pi acceptors, it is possible to verify a comm n shielding effect on these ligand protons for all the
complexes up to −0.45 ppm at H3, indicative of pi-backdon on. Complex 3 has the ost deshielded
H3 proton, as it as an alkyl substituent at the para positio of t phenyl group. This substit ent is a
ring activator, possibly leading to an elongation of the aromatic pi-system. On the contrary, complex
5 has the most shielded H3 proton due to the presence of the electronegative bromine that pulls the
electronic density. The 4-chlorocinnamonitrile ligand that was used for the synthesis of complex 6 was
a mixture of cis (40%) and trans (60%) forms. The resulting complex maintained the same proportion
between the two isomers, being easily identified by H2 and H3 coupling constants (JHH = 16 Hz for
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the trans isomer and JHH = 12 Hz for the cis isomer). In this case, the shieling effect is mostly felt at
trans-H3 (−0.54 ppm).
Table 1. Selected 1H NMR chemical shifts (ppm). The spectra were obtained in acetone-d6. Values in
brackets represent the differences on H3 between the coordinated and free nitrile.
Complex (η5-C5H5) H3
[Fe(η5-C5H5)(CO)(PPh3)I] 4.57 -
1 5.21(+0.64)
7.37
(−0.37)
2 5.17(+0.60)
7.19
(−0.43)
3 5.20(+0.63)
7.48
(−0.26)
4 5.13(+0.56)
6.97
(−0.42)
5 5.21(+0.64)
7.31
(−0.45)
13C{1H} NMR data show the Cp ring at the usual chemical shift for monocationic Fe(II) compounds
and a significant deshielding (up to +44 ppm) on the C1 (C≡N) upon nitriles coordination. The 31P{1H}
spectrum is characterized by the presence of a single signal at 66 ppm for all of the compounds.
2.3. FTIR Spectroscopy
The solid state FTIR spectra (KBr pellets) of all the complexes present the characteristic bands for
the cyclopentadienyl ring along with the aromatic rings of the triphenylphosphane and nitrile ligands
(3200–3000 cm−1 and 1600–1400 cm−1). Additional bands at ~1250, 1160, and 1029 cm−1 confirm
the presence of the counter-ion (CF3SO3)−. The presence of coordinated carbonyl can be confirmed
by the infrared stretching vibration, appearing at 1956–1996 cm−1. The replacement of the iodide
in [Fe(η5-C5H5)(CO)(PPh3)I] by the nitrile ligand in compounds 1–6 leads to a strengthening of the
(C≡O) bond (1935 vs. 1956–1996 cm−1) and it accounts for the pi-backdonation competition with the
other pi-acceptor nitrile ligands (Table 2). It is also possible to observe a significant variation between
complexes 5 and 6 with respect to the vibration frequency of the coordinated carbonyl, which was
related with the nitrile substituent. Complex 5 is a benzonitrile substituted at the para position with a
bromine, which is an electronegative atom that acts as an inducting withdrawing group.
Table 2. Characteristic stretching frequencies (cm−1). Values in brackets represent the differences
between the υ(N≡C) of coordinated and free nitrile or between the υ(CO) of [Fe(η5-C5H5)(CO)(PPh3)I]
and compounds 1–6.
Complex υN≡C υCO
[Fe(η5-C5H5)(CO)(PPh3)I] - 1935
1 2247(+19)
1977
(+42)
2 2249(+16)
1986
(+51)
3 2250(+23)
1984
(+49)
4 2237(+23)
1980
(+45)
5 2245(+22)
1996
(+61)
6 2241(+25)
1956
(+21)
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The coordination of the nitriles to the iron center can be confirmed by the characteristic stretching
vibration of the nitrile functional group appearing at 2237–2250 cm−1 (Table 2). This variation of
16–25 cm−1 for the υ(N≡C) when compared with the free ligand accounts for the σ coordination and
the effect of metal-ligand pi-backdonation through dmetal−pi*ligand interaction that was observed in
other related compounds [23].
2.4. UV-VIS Spectroscopy
The UV-Visible study of the compounds 1–6 was performed in DCM and DMSO solutions
(10−3–10−5 M) in the spectral window that was allowed by the solvents. All of the compounds have in
common pi→pi* transitions below 285 nm, attributed to intraligand transitions (Figure 2), which usually
occur in aromatic and chromophoric ligands, such as the phosphane and nitriles. One can also
observe a shoulder at around 300–330 nm that was attributed to electronic transitions occurring in the
organometallic fragment {FeCp}+ (by analogy with the iron parental complex [Fe(Cp)(CO)2I]) [20].
In addition, two bands/shoulders were found for all of the complexes. The first one around 400 nm,
with values of ε ~1000 M−1cm−1, is probably a metal-to-ligand charge transfer band (MLCT), since the
other techniques used (1H NMR and FT-IR) showed the presence of pi-backdonation from the metal
center to the nitrile and to the carbonyl; however, other contributions cannot be excluded. The second
shoulder, above 500 nm, may be a d-d band, as it is common to all complexes and it has values of
ε < 500 M−1cm−1. This point will be further clarified below (TD-DFT calculations).
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2.5. Single-Crystal Structures of Compounds 1, 4 and 5
Compounds [Fe(η5-Cp)(CO)(PPh3)(NCPh)][CF3SO3] 1, [Fe(η5-Cp)(CO)(PPh3)(p-NCPhNH2)]
[CF3SO3] 4, and [Fe(η5-Cp)(CO)(PPh3)(p-NCPhBr)][CF3SO3] 5 crystallize from acetone/n-hexane
solutions as orange blocks (crystal dimensions 0.23 × 0.14 × 0.07 mm), orange needles (crystal
dimensions 0.15 × 0.10 × 0.04 mm), or orange plates (crystal dimensions 0.25 × 0.04 × 0.03 mm),
respectively. Figure 3 shows the ORTEP representations of these compounds.
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Figure 3. ORTEP for he cations of complexes (A) [Fe(η5-Cp CO)(PPh3)(NCPh)]+ 1,
(B [Fe(η5-Cp CO)(P 3)(p-NCPhNH2)]+ 4 and (C) [Fe(η5-Cp)(CO)(PPh3)(p-NCPhBr)]+ 5. All of the
non-hydrogen atoms are pr sented by their 50% probability ell p oids. Hydrogen atoms are omitted
fo clarity.
All the co pounds crystallize in a centrosy etric onoclinic, P2 c, space group. In the
olecular structures, the iron centres adopt a “piano stool” distribution formed by the iron-Cp unit
bound to one phosphine, one olecule, and one of different benzonitrile olecules. The -
bond lengths are bet een 1.13–1.16 (see Table S1), and they decrease in the sequence p- > p-
> p-Br, which indicates that an increased contribution of resonance structure due to an increase in
the character pi-acceptor of the ligand and/or the effect of the electronegativity of p-substituent in
benzonitrile olecules causes that the Fe back-bonding into the CO pi* orbital is less important and the
distance increases [24]. An increase of strong pi-acceptor character in benzonitrile molecules, compete
with CO molecule for the electron back-donation and the CO stretch frequencies remain high, as also
observed by the FTIR stretching frequencies as well [25]. The distances between Fe and the centroids
of the pi-bonded cyclopentadienyl moiety to Fe centre are: 1.7158(17) Å (ring slippage 0.043 Å) in
complex 1, 1.7166(10) Å (ring slippage 0.046 Å) in complex 4, and 1.7135(18) Å (ring slippage 0.042 Å)
in complex 5. The mean values of the Fe-C bond distances are: 2.095(4) in 1, 2.096(2) Å in 4 and 2.099(4)
in 5. Table S1 contains selected bond lengths and angles for all of the compounds.
Short contacts are observed between the phenyl rings of phosphane ligands and Cp rings (see
Figure 4A). The distance C(3)-C(16) is 3.172(3) Å and C(4)-C(16) is 3.298(3) Å (through symmetry
operation, 1 − x, −y, 2 − z) in complex 1 and C(2)-C(22) is 3.343(2) Å and C(3)-C(22) is 3.201(2) Å
(through symmetry operation, -x,-y,-z) in complex 4. CH-pi-carbon atom of phosphine phenyl ring
interaction appears in the crystal packing of complex 4 [distance C(11)-H(22): 2.842(2) Å] (see Figure 4).
A pi-pi lateral interaction is observed between NCPh-ρ-Br rings in complex 5 (see Figure 5), which is the
predominant interaction and determines the crystal packing in this compound. The distance between
centroids, dc1-c2, is 3.531(2) Å [c1, C(9C)-C(10C), c2, C(9E)-C(10E)]. Hydrogen bonds are present in the
structure of pNH2-derivative (4). Intermolecular hydrogen bond between N(2)-O(3) [d(D-H): 0.96(3) Å,
d(D...A): 2.21(3) Å, d(D...A): 3.112(3)Å and <(DHA): 157(2)◦, symmetry transformation: −x, y − 1/2, −z
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+ 3/2] is the unique that is observed. Different types of intermolecular interactions can also occur when
these compounds interact with biomolecules and they can justify their different biological activities.
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2.6. TD-DFT Calculations 
Figure 5. Crystal packing of the compound [Fe(η5-Cp)(CO)(PPh3)(p-NCPhBr)][CF3SO3] 5 (left; drawing
were done with SHELXTL program by balls and sticks). Short contacts between complexes are showed
in dashed black lines (right; drawing was done with SHELXTL program by their 50% probability
ellipsoids). Hydrogen atoms are omitted for clarity.
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2.6. TD-DFT Calculations
TD-DFT calculations (PBE0) were performed in dichloromethane for all complexes to help in the
interpretation of the UV-Vis. data (see computational details). Table S2 lists the relevant calculated
excitations. The TD-DFT excitations reproduce the two low-energy shoulders that were experimentally
observed for all complexes (>500 nm and ~400 nm) with a perfect quantitative agreement. Indeed,
the superposition of the experimental spectra with the calculated excitations, as shown in Figure 6,
is remarkable.
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dichloromethane for complexes 1–6. The excitations reported in Table S2 are highlighted (*/**).
In all complexes, the low-energy excitations are dominated by two transitions (* and ** in
Figure 6) whose compositions are highly mixed (Table S2), with contributions from several orbitals.
Electron density difference maps (EDDM), which represent the changes in electron density upon
excitation, were also obtained in order to assist the assignment of the transitions (Figure 7). Surprisingly,
for most complexes, the two low-energy excitations have very similar character apart from complex 4,
where slightly different EDDMs are observed (see below). For complexes 1, 3, and 5, both of the
excitations have d-d character mixed with charge transfer from iron center (and NC bond) to the PPh3
ligand (MLCT). On the other hand, for complexes 2 and 6, besides the mixed d-d/MLCT character,
there is a clear participation of the nitrile ligand, i.e., there is a charge transfer from Fe-nitrile ligand to
the PPh3 ligand. In complex 4, the lowest-energy excitation resembles the ones that were obtained for 1,
3, and 5, whereas the second excitation is similar to the ones observed for 2 and 6 with the participation
of the nitrile ligand.
Molecules 2020, 25, 1592 9 of 22olecules 2020, 25, x FOR PEER REVIEW 9 of 22 
 
 
Figure 7. Electron density difference maps (EDDM) for complexes 1–6 for excitations presented in 
Table S2 and highlighted in Figure 6 with * and **. Violet and green correspond to a decrease and 
increase of electron density, respectively. 
2.7. Biological Assays 
2.7.1. Stability assays 
For the intended application as anticancer agents, it is desirable that the compounds under study 
are stable in cellular medium. Thus, the stability of these compounds has been tested by UV-Vis. 
spectroscopy in 100% DMSO (Figure S37), which is the co-solvent that is used for the biological 
studies, and in culture cellular media (DMEM) while using 5% of DMSO (Figure S38). Under these 
conditions, all of the compounds were very stable up to 24 h, with absorbance variations of less than 
5%. 
2.7.2. In Vitro Cytotoxicity Evaluation and IC50 Determination 
The cytotoxic activity of these new [Fe(η5-C5H5)(CO)(PPh3)(NCR)][CF3SO3] compounds (abrev. 
‘FeCp’) was assessed in the triple negative breast cancer-derived cell line MDA-MB-231, in the 
colorectal cancer-derived cell line SW480 and in the noncancerous cell line NCM460, derived from 
normal colon epithelial cells. All of the cells were incubated for 48 h with different concentrations of 
all iron compounds. All the nitrile organic ligands were also tested in the MDA-MB-231 cell line. 
These cell lines were chosen due to the high incidence and prevalence of these cancers and since there 
is no currently available treatments for them. Indeed, breast and colorectal cancers are among the top 
three causes of cancer death worldwide. All of the complexes are very active compounds in the 
colorectal cancer cells SW480, as well as for breast cancer cells MDA-MB-231 (Table 3). None of the 
nitrile ligands was cytotoxic up to 100 µM. All of the ‘FeCp’ compounds affected the cell growth of 
SW480 and MDA-MB-231 cell lines in the micromolar range, being more cytotoxic for the breast 
cancer cells. The noncancerous cell line NCM460 was shown to be more resistant to the treatment 
with the ‘FeCp’ compounds. The half-maximal inhibitory concentration (IC50) that was determined 
for SW480 cell line, for all compounds, was half of the IC50 values determined in the “normal” cell 
line NCM460. These results suggest that these compounds are more cytotoxic in cancer cells than in 
“normal” cells (Table 3), showing a higher IC50 for NCM460 cell line, for all six compounds. These 
results are a good starting point, since it is expected that, during a chemotherapy cycle, the dosage of 
Figure 7. Electron density difference maps (EDDM) for complexes 1–6 for excitations presented in
Table S2 and highlighted in Figure 6 with * and **. Violet and green correspond to a decrease and
increase of electron density, respectively.
2.7. Biological Assays
2.7.1. Stability Assays
For the intended application as anticancer agents, it is desirable that the compounds under study
are stable in cellular medium. Thus, the stability of these compounds has been tested by UV-Vis.
spectroscopy in 100% DMSO (Figure S37), which is the co-solvent that is used for the biological studies,
and in culture cellular media (DMEM) while using 5% of DMSO (Figure S38). Under these conditions,
all of the compounds were very stable up to 24 h, with absorbance variations of less than 5%.
2.7.2. In Vitro Cytotoxicity Evaluation and IC50 Determination
The cytotoxic activity of these new [Fe(η5-C5H5)(CO)(PPh3)(NCR)][CF3SO3] compounds (abrev.
‘FeCp’) was assessed in the triple negative breast cancer-derived cell line MDA-MB-231, in the colorectal
cancer-derived cell line SW480 and in the noncancerous cell line NCM460, derived from normal
colon epithelial cells. All of the cells were incubated for 48 h with different concentrations of all iron
compounds. All the nitrile organic ligands were also tested in the MDA-MB-231 cell line. These cell
lines were chosen due to the high incidence and prevalence of these cancers and since there is no
currently available treatments for them. Indeed, breast and colorectal cancers are among the top three
causes of cancer death worldwide. All of the complexes are very active compounds in the colorectal
cancer cells SW480, as well as for breast cancer cells MDA-MB-231 (Table 3). None of the nitrile
ligands was cytotoxic up to 100 µM. All of the ‘FeCp’ compounds affected the cell growth of SW480
and MDA-MB-231 cell lines in the micromolar range, being more cytotoxic for the breast cancer cells.
The noncancerous cell line NCM460 was shown to be more resistant to the treatment with the ‘FeCp’
compounds. The half-maximal inhibitory concentration (IC50) that was determined for SW480 cell line,
for all compounds, was half of the IC50 values determined in the “normal” cell line NCM460. These
results suggest that these compounds are more cytotoxic in cancer cells than in “normal” cells (Table 3),
showing a higher IC50 for NCM460 cell line, for all six compounds. These results are a good starting
point, since it is expected that, during a chemotherapy cycle, the dosage of the drug should kill cancer
cells without affecting the normal and healthy cells of the organism. The selectivity index (SI) is an
Molecules 2020, 25, 1592 10 of 22
index value that gives an idea about the selectivity of a compound. For almost all of the compounds,
the selectivity indices were equal or greater than two (Table 3). Some authors consider this value to
be an interesting selectivity index, meaning that the compound show the double of the cytotoxic to
the tumor cells when comparing to the normal cells [26]. The obtained results are in line with what is
intended in the clinics, since they suggest that the dose used to affect tumor cells will not affect the
normal and healthy cells of the patient.
Table 3. IC50 values determined at 48 h incubation of iron compounds (1–6) against MDA-MB-231
breast cancer cells, SW480 colorectal cancer cells and noncancerous cell line NCM460, derived from
normal colon epithelial cells.
IC50 (µM)
Compounds MDA-MB-231 SW480 NCM460 Selectivity Index
1 0.45 ± 0.02 1.5 ± 0.2 3.8 ± 0.6 2.5
2 0.71 ± 0.05 3.0 ± 0.3 7.8 ± 1.2 2.6
3 0.37 ± 0.04 3.0 ± 0.2 11.7 ± 1.8 3.9
4 0.19 ± 0.01 1.0 ± 0.1 2.4 ± 0.5 2.4
5 0.91 ± 0.05 1.5 ± 0.1 3.0 ± 0.4 2.0
6 0.39 ± 0.02 1.0 ± 0.1 1.8 ± 0.1 1.8
When comparing these results with related ‘RuCp’ compounds, similar IC50 values were observed
for the SW480 cell line [17], while, for the MDA-MB-231 cell line, the new compounds here reported
seem to show better cytotoxicity [14]. Although direct comparison with other ‘FeCp’ compounds
is not possible due to differences in cell lines and incubation times, the results from the literature
for [Fe(Cp)(dppe)(nitrile carbohydrate derivatives)]+ in the colon cancer HCT116 cell line (72 h
incubation) [27] indicate that the results reported here are very promising. Additionally, regarding
our previous work on similar compounds with different substituents on the phosphane ligands,
[Fe(η5-Cp)(CO)(phosphane)(aminobenzonitrile)]+ [20], one can infer that the changes introduced at
the nitrile ligand seem to impart better cytotoxicity.
2.7.3. Iron Compounds Reduce the Colony Formation Ability of SW480 Colorectal Cancer Cells
The lack of success of some chemotherapeutic treatments is due to the fact that, even after several
cycles of chemotherapy, some cells may relapse and maintain their malignant potential. In this way, the
effects on cell survival and proliferation of iron-based compounds was assessed by colony formation
assay. This technique allows for determining the cellular ability to survive to the exposure of an
exogenous agent for a short period of time and produce colonies after that agent is removed, simulating
in vitro what happens during cycles of chemotherapy. The SW480 colorectal cancer cell line was
incubated with 14 IC50 and IC50 concentrations of the Fe compounds, during 48 h. Cisplatin was used
as the positive control. The results showed that the conditions that were treated with the IC50 values of
Fe compounds have significantly affected the colony formation ability of SW480 cells (Figure 8 and
Figure S39). Regarding cisplatin, in both conditions, the compound completely inhibited the formation
of colonies. The compounds with the lowest IC50 values (Table 3) are those that are inhibiting the
ability to form colonies to a large extent (1, 4, 5, and 6; assays done at IC50).
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Figure 8. Iron compounds affect the colony formation ability of SW480 cell line. Analysis of the
colony formation ability, after 48 h of incubation with 14 IC50 and IC50, in SW480 cell line. The values
represent mean ± S.D. of at least three independent experiments. Statistical analysis was performed by
one-way ANOVA with Dunnett’s multiple comparisons test. ** P ≤ 0.01; **** P ≤ 0.0001 compared with
negative control.
2.7.4. [Fe(η5-C5H5)(CO)(PPh3)(NCR)][CF3SO3] Compounds Induce Apoptosis in SW480 Colorectal
Cancer-Derived Cell Line
The cell death mechanism of iron compounds was determined using Annexin V/Propidium
iodide (AV/PI) cytometry-based assay. Annexin V binds with high affinity to the phospholipid
phosphatidylserine (PS) that was present in the membrane. PS translocation from the inner side of the
plasma membrane to the surface is an early event of apoptosis (AV + PI−). On the other hand, when the
integrity of the membrane is compromised, PI binds with DNA, allowing for the distinction between
late apoptosis (AV + PI+) or necrosis (AV−PI+). The SW480 cells were incubated with the compounds,
for 48 h, at their IC50 and 2 × IC50 values and cisplatin was used as the positive control. The results
showed that incubation with the ‘FeCp’ compounds led to an increase in the percentage apoptotic cells
(AV + PI− and AV + PI+) (Figure 9a and Figure S40). This is more evident when we put together the
percentage of early apoptotic cells (AV + PI−) and the late apoptotic cells (AV + PI+), which correspond
to the total levels of apoptosis (see Figure 9b). We could observe that, with the exception of compound
2, all of the ‘FeCp’ compounds induce apoptosis at statistically significant levels when comparing with
the negative control, although compounds 3 and 5 only reach statistical significance with the 2 × IC50
dose. We can also observe a dose/effect for compounds 3, 4, and 5, although not so evident as cisplatin.
We also showed that the conditions that were treated with cisplatin had higher levels of apoptosis than
conditions incubated with ‘FeCp’ compounds. Regarding necrotic cells, these cells are represented by
AV−PI+ staining (in blue), and, as observed in Figure 9a, there is a low percentage of necrotic cells
induced by the compounds which are not significantly different from the negative control. Therefore,
these results indicate that ‘FeCp’ compounds do not induce necrosis. Overall, compounds 1, 4, 5, and 6,
in addition to inhibiting the formation of colonies and having the lowest IC50 values, they also induce
Molecules 2020, 25, 1592 12 of 22
apoptosis in a significant manner. Thus, these compounds stand out from the remaining compounds
due to their promising results.
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Figure 9. ‘FeCp’ compounds induce apoptosis in SW480 colorectal cancer-derived cell line. Apoptotic
cell d ath was analyzed by A nexin V fluore cein isothiocyanate (AV-FITC) and propid um iodide (PI)
assay in SW480 ce ls, after incubation with IC50 and 2 × IC50 concentrations for 48 h. (a) Analysis of
AV/PI ssay in SW480 cells. Values represen mean ± S.D. of at least three ndependent experiments.
Statistical analysis was p rformed by two-way ANOVA with Dunnett’s multiple comparisons te t.
(b) Graphical representation of the total percentage of apoptotic cells (early apo tosis (AV + PI−) and
late apoptosis (AV + PI+)). Statistical analysis was performed by one-way ANOVA with Dunnett’s
multi le c mparisons test. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 when compared with the
negative control.
2.7.5. [Fe(η5-C5H5)(CO)(PPh3)(NCR)][CF3SO3] Compounds Affect the Actin Cytoskeleton of SW480
Colorectal Cancer Cells
With the purpose of evaluating the effects of these new compounds in the cytoskeleton structure
of SW480 colorectal cancer-derived cell line, the F-actin organization and morphology was analyzed
while using phalloidin. The cells were treated with IC50 concentrations of each compound, for 48 h,
and then were stained with Phalloidin-AlexaFluor® 568. In the negative control, we observed that cells
are bigger, with a well-marked and enlarged cytoskeleton around the nucleus. We can also distinguish
the establishment of connections between cells showing filipodia-like structures. In the conditions that
were treated with cisplatin and compounds 1, 2, 4, 5, and 6, the cells are smaller and rounded, losing
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the filipodia-like structures (Figure 10). In these conditions, we observed that the cytoskeleton is just
around the nucleus in a thin line. Cisplatin and compounds 1, 4, and 6 also decreased the cell number,
showing an increase in the distance between cells affecting the cell-cell adhesions and intercellular
contacts establishment, thus decreasing the communication between cells. Compound 3 affected the
actin cytoskeleton in a less perceptible way, decreasing the size of some cells and leading to a rounding
phenotype of others. In general, the results showed that the compounds with the lowest IC50 values
have a pronounced effect on the inhibition of colony formation, an increase in apoptosis with low
doses of the compounds, and alteration on the actin cytoskeleton morphology suggesting a cytotoxic
effect of these agents in SW480 colorectal cells.
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Figure 10. ‘FeCp’ compounds affect the cytoskeleton of SW480 colorectal cancer-derived cell line.
The analysis of F-actin staining was performed using the IC50 values of each compound, for 48 h.
Representative images (×600) of DAPI (4’,6-diamidino-2-phenylindole), Phalloidin-AlexaFluor® 568
and merged were obtained in a fluorescence microscope. The results were obtained from at least three
independent experiments.
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3. Materials and Methods
All of the reactions and organometallic synthesis were carried out under nitrogen atmosphere
while using standard Schlenk techniques. The solvents used were previously and they were freshly
distilled under nitrogen atmosphere before use, according to common literature methods. The NMR
spectra were recorded on a Brucker Advance 400 spectrometer (Fällanden, Switzerland) (1H, 400 MHz;
13C{1H}-apt, 100.62 MHz; 31P{1H}, 161.97 MHz) at probe temperature. 1H and 13C chemical shifts were
reported downfield from the residual solvent peak, whereas the 31P NMR chemical shifts were reported
downfield from the external standard 85% H3PO4. All of the resonances were characterized for their
chemical shifts (δ), given in parts-per-million (ppm), and for their coupling constants (J) expressed in
Hertz (Hz). Resonance multiplicity is expressed, as follows: singlet (s), doublet (d), triplet (t), multiplet
(m), and complex (comp). All of the assignments were attributed using HMBC, HMQC, and COSY
2D-RMN techniques. Each sample was prepared under air and at room temperature, while using the
most adequate deuterated solvent. The electronic UV-Vis spectra were recorded in dichloromethane
and dimethylsulfoxide solutions (10−3–10−5 M), under air, using 1 cm optical path quartz cells on a
Jasco V-660 spectrometer (Elnor, Porto, Portugal) in the range of 200–900 nm. The infrared spectra were
recorded in a Shimadzu IRAffinity-1 FTIR spectrophotometer (Kyoto, Japan) in dry KBr pellets, under
air, and at room temperature. Elemental analyses were obtained at Laboratório de Análises, Instituto
Superior Técnico, using a Fisons Instruments EA1108 system (Fison Instruments Ltd., Glasgow, UK).
Data acquisition, integration, and handling were performed using a PC with the software package
EAGER-200 (Carlo Erba Instruments).
For the thin layer chromatography (TLC-PET) analytical assays, aluminum oxide on PET of
several appropriate dimensions was used. The elution of these plates was performed while using
different proportions of acetone/n-hexane. Upon elution, the TLC plates were observed under UV light
at 254 and 366 nm.
3.1. Synthesis
The starting material, [Fe(η5-C5H5)(CO)2I], was prepared from the commercially available dimer
following the literature procedure [28].
3.1.1. Synthesis of [Fe(η5-C5H5)(CO)(PPh3)(I)]
The synthesis of the complex [Fe(η5-C5H5)(CO)(PPh3)I] has been previously reported [20,24]. Yet,
in this protocol, we increased the yield from 69 to 75% [20]
To a stirred and degassed solution of [Fe(η5-C5H5)(CO)2I] (1.8 mmol) in dry acetone (40 mL),
PPh3 (1.8 mmol) was added. The reaction mixture was then irradiated under UV light of 300 W for 3 h.
The solvent was removed under vacuum and the obtained product was dissolved in the minimum
quantity of dry acetone to remove the soluble impurities. A green powder precipitated (the product)
and the impurity was separated by cannula-filtration. The residue was twice recrystallized from dry
acetone/n-hexane and dark green products are obtained.
Yield: 80%. Green powder. The obtained NMR results are in agreement with the values that
were found in the literature [20] FTIR (KBr, cm−1): υ(C-H aromatics) 3100–3000, υ(C≡O) 1935, υ(C-C
aromatics) 1600–1400. UV-Vis in DMSO, λmax/nm [ε/M−1 cm−1]: 275 (Sh); 325 (2470); 387 (Sh); 448 (760);
626 (155). UV-Vis in DCM, λmax/nm [ε/M−1 cm−1]: 237 (21000); 241 (22765); 326 (2686); 445 (800); and,
618 (200).
3.1.2. General Procedure for the Synthesis of [Fe(η5-C5H5)(CO)(PPh3)(NCR)][CF3SO3] Complexes 1–6
AgCF3SO3 (0.8 mmol) and the respective nitrile (0.5 mmol) were added to a stirred and degassed
solution of [Fe(η5-C5H5)(CO)(PPh3)I] (0.5 mmol) in dry acetone (30 mL) and the reaction was followed
for 24 h at room temperature, monitored by 1H and 31P NMR or TLC. The precipitates were separated
by cannula-filtration and the solvent was evaporated under vacuum. The product is purified by column
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chromatography, always using a mixture of acetone/n-hexane with different proportions, according to
each product.
3.1.3. [Fe(η5-C5H5)(CO)(PPh3)(NCPh)][CF3SO3]—Complex 1
Yield: 69%, Red crystalline powder. Eluent: acetone/n-hexane (1:1).
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 7.70 (t, 1, H5); 7.66–7.57 (comp, 9, Hmeta+Hpara-PPh3); 7.53–7.49
(m, 6, Hortho-PPh3); 7.37 (d, 2, H3); 7.3 (t, 2, H4); 5.21 (s, 5, (η5-C5H5)). 13C NMR [(CD3)2CO-d6, Me4Si,
δ/ppm]: 216.35 (d, JCP = 28, C≡O); 157.24 (C1); 135.38 (C2); 134.09 (C5); 133.02 (d, 2JCP = 10, Cortho-PPh3);
132.45 (C3); 131.92 (d, 1JCP = 46, Cipso-PPh3); 131.22 (d, 4JCP = 3, Cpara-PPh3); 129.09 (d,3JCP = 10,
Cmeta-PPh3); 128.97 (C4); 85.15 (η5-C5H5). 31P NMR [(CD3)2CO-d6, H3PO4, δ/ppm]: 66.55. FTIR [KBr
cm−1]: υ(C-H aromatics) 3150, 3091, 3050; υ(N≡C) 2247; υ(C≡O) 1977; υ(CF3SO3−) 1257, 1157, 1029.
UV-Vis in DMSO, λmax/nm[ε/M−1cm−1]: 272 (11092); 275 (11093); 278 (11093); 282 (Sh); 285 (Sh); 290
(Sh); 331 (Sh); 401 (Sh); 501 (Sh). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]: 235 (14060); 238 (17100); 240
(16560); 247 (14300); 269 (12130); 286 (9500); 335 (4220); 390 (990); 502 (225). ESI-MS (+, m/z) Calc for
[1]+: 514.10. Found: 513.66. Elemental analysis (%) Calc. for C32H25F3FeNO4PS. C 57.9; H 3.7; N 2.1; S
4.8; Found: C 57.6; H 3.6; N 1.8; S 5.0.
3.1.4. [Fe(η5-C5H5)(CO)(PPh3)(p-NCPhOH)][CF3SO3]—Complex 2
Yield: 66%. Red crystalline powder. Eluent: acetone/n-hexane (3:1). An increasing proportion of
acetone is used until the product is completely extracted.
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 9.82 (s, 1, OH); 7.66–7.56 (comp, 9, Hmeta+Hpara-PPh3); 7.53
(t, 6, Hortho-PPh3); 7.19 ( d, JHH = 20, H3); 6.90 (d, JHH = 20, H4); 5.17 (s, 5, (η5-C5H5)). 13C NMR
[(CD3)2CO-d6, Me4Si, δ/ppm]: 217.66 (d, JCP = 28, C≡O); 163.64 (C1); 137.45 (C2); 135.48 (C3); 134.06
(d, 2JCP = 10, Cortho-PPh3); 133.11 (d, 1JCP = 46, Cipso-PPh3); 132.25 (d, 4JCP = 3, Cpara-PPh3); 130.12
(d, 3JCP = 10, Cmeta-PPh3); 117.16 (C4); 101.53 (C5); 86.01 (η5-C5H5). 31P NMR [(CD3)2CO-d6, H3PO4,
δ/ppm]: 66.62. FTIR [KBr cm−1]: υ(O-H) 3217; υ(C-H aromatics) 3080, 2962; υ(N≡C) 2249; υ(C≡O) 1986;
υ(CF3SO3−) 1261, 1160, 1026. UV-Vis in DMSO, λmax/nm[ε/M−1cm−1]: 273 (16461); 278 (16075); 288 (Sh);
330 (Sh); 408 (Sh); 507 (Sh). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]: 238 (12575); 242 (11880); 247 (11150);
250 (10100); 267 (7320); 274 (7010); 293 (5080); 313 (2860); 407 (492); 507 (143); 546 (103). ESI-MS(+, m/z)
Calc for [2]+: 530.09. Found: 529.68. Elemental analysis (%) Calc. for C32H25F3FeNO5PS. C 56.5; H 3.7;
N 2.0; S 4.7; Found: C 54.5; H 3.6; N 2.0; S 5.0;
3.1.5. [Fe(η5-C5H5)(CO)(PPh3)(p-NCPhCH2OH)][CF3SO3]—Complex 3
Yield: 65%. Red crystalline powder. Eluent: acetone/n-hexane (2:1). An increasing proportion of
acetone is used until the product is completely extracted.
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 8.61 (s, 1, OH); 7.65–7.58 (comp, 9, Hmeta+Hpara-PPh3); 7.54 (t, 6,
Hortho-PPh3); 7.48 (d, JHH = 20, H3); 7.30 (d, JHH = 10, H4); 5.20 (s, 5,(η5-C5H5)); 4.85 (s, 1, OH). 13C NMR
[(CD3)2CO-d6, Me4Si, δ/ppm]: 217.35 (d, JCP = 28, C≡O); 153.04 (C1); 136.66 (C2); 133.95 (d, 2JCP = 10,
Cortho-PPh3); 133.25 (C3); 132.80 (d, 1JCP = 46, Cipso-PPh3); 132.17 (d, 4JCP = 2, Cpara-PPh3); 130.00 (d,3JCP
= 10, Cmeta-PPh3); 127.40 (C4); 109.40 (C5); 86.01(η5-C5H5); 63.81 (C6). 31P NMR [(CD3)2CO-d6, H3PO4,
δ/ppm]: 66.51. FTIR [KBr cm−1]: υ(O-H) 3450; υ(C-H aromatics) 3109, 2954; υ(C-H aliphatic) 2870;
υ(N≡C) 2250; υ(C≡O) 1984; υ(CF3SO3−) 1273, 1161, 1029. UV-Vis in DMSO, λmax/nm[ε/M−1cm−1]: 274
(6050); 278 (5995); 285 (Sh); 289 (Sh); 331 (Sh); 403 (563); 502 (Sh). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]:
236 (31670); 240 (29770); 271 (15930); 325 (5865); 397 (1290); 546 (217); 623 (54). ESI-MS(+, m/z) Calc for
[3]+: 544.11. Found: 543.67. Elemental analysis (%) Calc. for C33H27F3FeNO5PS. C 57.1; H 3.9; N 2.0; S
4.6; Found: C 56.4; H 3.7; N 1.8; S 5.0;
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3.1.6. [Fe(η5-C5H5)(CO)(PPh3)(p-NCPhNH2)][CF3SO3]—Complex 4
Yield: 79%. Red crystalline powder. Eluent: acetone/n-hexane (2:1).
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 7.64–7.57 (comp, 9, Hmeta+Hpara-PPh3); 7.55 (t, 6, Hortho-PPh3);
6.97 (d, JHH = 20, H3); 6.64 (d, JHH = 10, Hortho-PPh3); 5.23 (s, 2, NH2); 5.13 (s, 5,(η5-C5H5)). 13C NMR
[(CD3)2CO-d6, Me4Si, δ/ppm]: 217.30 (d, JCP = 28, C≡O); 154.14 (C1); 138.30 (C2); 134.46 (C3); 133.46 (d,
2JCP = 10, Cortho-PPh3); 132.66 (d, 1JCP = 47, Cipso-PPh3); 131.62 (d, 4JCP = 2, Cpara-PPh3); 129.50 (d,3JCP
= 10, Cmeta-PPh3); 113.86 (C4); 95.69 (C5); 85.31 (η5-C5H5). 31P NMR [(CD3)2CO-d6, H3PO4, δ/ppm]:
66.68. FTIR [KBr cm−1]: υ(N-H) 3415; υ(C-H aromatics) 3238, 3108, 2985; υ(N≡C) 2237; υ(C≡O) 1980;
υ(CF3SO3−) 1257, 1172, 1029. UV-Vis in DMSO, λmax/nm[ε/M−1cm−1]: 273 (Sh); 278 (18759); 283 (18924);
290 (17987); 320 (Sh); 404 (Sh); 520 (Sh). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]: 235 (23100); 253 (19240);
271 (19000); 304 (14070); 406 (1245); 525 (440). ESI-MS (+, m/z) Calc for [4]+: 529.11. Found: 528.71.
Elemental analysis (%) Calc. for C32H26F3FeN2O4PS. C 56.6; H 3.9; N 4.1; S 4.7; Found: C 53.4; H 4.0; N
3.5; S 5.0.
3.1.7. [Fe(η5-C5H5)(CO)(PPh3)(p-NCPhBr)][CF3SO3]—Complex 5
Yield: 72%, Red crystalline powder. Eluent: acetone/n-hexane (1:1).1H NMR [(CD3)2CO-d6, Me4Si,
δ/ppm]: 7.72 (d, JHH = 20, H4); 7.66–7.58 (comp, 9, Hmeta+Hpara-PPh3); 7.53 (t, 6, Hortho-PPh3); 7.31
(d, JHH = 20, H3); 5.21 (s, 5, (η5-C5H5)). 13C NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 217.14 (d, JCP =
27, C≡O); 135.45 (C1); 134.97 (C4); 133.95 (d, 2JCP = 10, Cortho-PPh3); 133.23 (C3); 132.74 (d, 1JCP =
46, Cipso-PPh3); 132.17 (d, 4JCP = 2, Cpara-PPh3); 130.02 (d,3JCP = 10, Cmeta-PPh3); 129.61 (C2); 110.56
(C5); 86.11 (η5-C5H5). 31P NMR [(CD3)2CO-d6, H3PO4, δ/ppm]: 66.51. FTIR [KBr cm−1]: υ(C-H
aromatics) 3089, 3062; υ(N≡C) 2245; υ(C≡O) 1996; υ(CF3SO3−) 1270, 1157, 1029. UV-Vis in DMSO,
λmax/nm[ε/M−1cm−1]: 272 (16775); 275 (16600); 278 (Sh); 281 (15797); 288 (Sh); 337 (Sh); 406 (Sh); 506
(354). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]: 235 (29900); 240 (29685); 242 (29650); 248 (28870); 273
(15540); 279 (14735); 340 (5530); 404 (1337); 515 (323). ESI-MS(+, m/z) Calc for [5]+: 592.01. Found:
591.65. Elemental analysis (%) Calc. for C31H24BrF3FeNOP. C 51.7; H 1.8; N 1.9; S 4.3; Found: C 50.6; H
3.4; N 1.6; S 4.0;
3.1.8. [Fe(η5-C5H5)(CO)(PPh3)(p-NCCH=CHPhCl)][CF3SO3]—Complex 6
Yield: 75%, Red crystalline powder. Eluent: acetone/n-hexane (1:1).
FTIR [KBr cm−1]: υ(C-H aromatics) 3057, 2962; υ(N≡C) 2241; υ(C≡O) 1986; υ(CF3SO3−) 1253, 1170,
1029. UV-Vis in DMSO, λmax/nm[ε/M−1cm−1]: 274 (12115); 278 (12313); 282 (12095); 285 (Sh); 297 (Sh);
306 (Sh); 334 (Sh); 380 (Sh); 507 (Sh). UV-Vis in DCM, λmax/nm[ε/M−1cm−1]: 235 (23100); 244 (19645);
252 (19260); 258 (18840); 271 (19000); 278 (18215); 311 (13339); 409 (1233); 532 (408). ESI-MS(+, m/z) Calc
for [6]+: 574.07. Found: 573.65. Elemental analysis (%) Calc. for C34H26ClF3FeNO4PS C 56.4; H 3.62;
N 1.9; S 4.0; Found: C 57.2; H 3.4; N 1.7; S 4.0.
3.1.9. [Fe(η5-C5H5)(CO)(PPh3)(trans-NCCH=CHPhCl)][CF3SO3]
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 7.72–7.44 (comp, 19H, PPh3+H5+H6); 7.04 (d, JHH = 16, H3);
6.26 (d, JHH = 16, H2); 5.14 (s, 5, (η5-C5H5)). 13C NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 217.50 (d, JCP =
26, C≡O); 152.92 (C3); 138.12 (C7); 136.47 (C4); 134.16 (d, 2JCP = 10, Cortho-PPh3); 133.05 (d, 3JCP = 26,
C1); 133.08 (d, 1JCP = 46, Cipso-PPh3); 132.30 (Cpara-PPh3); 130.43 (C5); 130.24 (C6); 130.11 (d,3JCP = 10,
Cmeta-PPh3); 97.16 (C2); 86.17 (η5-C5H5). 31P NMR [(CD3)2CO-d6, H3PO4, δ/ppm]: 66.51. 31P NMR
[(CD3)2CO-d6, H3PO4, δ/ppm]: 66.39.
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3.1.10. [Fe(η5-C5H5)(CO)(PPh3)(cis-NCCH=CHPhCl)][CF3SO3]
1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 1H NMR [(CD3)2CO-d6, Me4Si, δ/ppm]: 7.72–7.44 (comp,
19H, PPh3+H5+H6); 7.38 (d, JHH = 16, H3); 5.76 (d, JHH = 16, H2); 5.19 (s, 5, (η5-C5H5)). 13C NMR
[(CD3)2CO-d6, Me4Si, δ/ppm]: 217.24 (d, JCP = 26, C≡O); 151.72 (C3); 137.56 (C7); 135.44 (C4); 134.06 (d,
2JCP = 10, Cortho-PPh3); 133.08 (d, 1JCP = 46, Cipso-PPh3); 132.84 (d, 3JCP = 26, C1); 132.30 (Cpara-PPh3);
131.06 (C5); 130.15 (d,3JCP = 10, Cmeta-PPh3); 129.99 (C6); 96.72 (C2); 86.17 (η5-C5H5). 31P NMR
[(CD3)2CO-d6, H3PO4, δ/ppm]: 66.51. 31P NMR [(CD3)2CO-d6, H3PO4, δ/ppm]: 65.38.
3.2. X-Ray Crystal Structure Determination
Three-dimensional X-ray data for [Fe(η5-Cp)(CO)(NCPh)(PPh3)][CF3SO3] 1,
[Fe(η5-Cp)(CO)(p-NCPhNH2)(PPh3)][CF3SO3] 4 and [Fe(η5-Cp)(CO)(p-NCPhBr)(PPh3)][CF3SO3] 5
were collected on a Bruker SMART Apex CCD diffractometer (Bruker España, Rivas-Vaciamadrid,
Madrid) at 100(2) K, using a graphite monochromator and Mo−Kα radiation (λ = 0.71073 Å) by the
φ-ω scan method. The reflections were measured from a hemisphere of data collected of frames
each covering 0.3 degrees in ω. A total of 49157 for 1, 105999 for 4 and 101816 for 5 reflections were
measured, all of which were corrected for Lorentz and polarization effects and for absorption by
semi-empirical methods that were based on symmetry-equivalent and repeated reflections. Of the
total, 3956 for 1, 5839 for 4, and 5616 for 5 independent reflections exceeded the significance level
|F|/σ(|F|) > 4.0. After data collection, in each case, a multi-scan absorption correction (SADABS) [29]
was applied, and the structures were solved by direct methods and refined by full matrix least-squares
on F2 data while using the SHELX suite of programs [30]. The structures were solved by direct
methods and refined by full-matrix least-squares methods on F2. The non-hydrogen atoms were
refined with anisotropic thermal parameters in all cases. The hydrogen atoms were located in
difference Fourier map and left to refine freely, except to for C(2) and C(3) in complex 5, which
were included in calculation positions and refined in the riding mode. A final difference Fourier
map showed no residual density outside: 0.631 and −0.461 e.Å−3 for 1, 0.378 and −0.365 e.Å−3 for
4 and 1.279 and −0.543 e.Å−3 for 5. A weighting scheme w = 1/[σ2(Fo2) + (0.034700 P)2 + 1.212300
P] for 1, 1/[σ2(Fo2) + (0.027800 P)2 + 2.298100 P] for 4 and 1/[σ2(Fo2) + (0.033400 P)2 + 8.005600
P] for 5, where P = (|Fo|2 + 2|Fc|2)/3, were used in the latter stages of refinement. CCDC No.
1985552-1985554 contain the supplementary crystallographic data for 1, 4, and 5. These data can be
obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033;
or e-mail: deposit@ccdc.cam.ac.uk. Table S4 illustrates crystal data and details of the data collection
and refinement for the new compounds.
3.3. TD-DFT Calculations
All of DFT calculations were performed with Gaussian09 [31] using the PBE0 functional [32]. For
iron and phosphorus, the LANL2TZ(f) and LANL08(d) basis sets with the associated effective core
potential were used, respectively [33,34]. For the other elements, a standard 6-311G** was employed.
After geometry optimization, TD-DFT calculations were performed, typically requesting the lowest
allowed 20 excitations. The effect of the solvent (dichloromethane) was accounted for using the SMD
solvation model, as implemented in Gaussian 09 [35]. The electron density difference maps (EDDMs)
were obtained while using the GaussSum package [36].
3.4. Biological Studies
3.4.1. Cell Lines and Culture Conditions
The colorectal cancer-derived cell line SW480 was obtained from American Type Culture Collection
(ATCC) (Manassas, VI, USA), and the noncancerous NCM460 cell line that was derived from normal
colon epithelial mucosa was obtained from INCELL’s (San Antonio, TX, USA) [37]. Both cell lines were
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maintained at 37 ◦C under a humidified atmosphere containing 5% CO2. The SW480 and NCM460
cells were grown in Roswell Park Memorial Institute (RPMI) (Biowest, Nuaillé, France), supplemented
with 10% FBS and 1% penicillin/streptomycin. The cells were subcultured once a week when 80% of
confluence was reached and, when necessary, seeded in sterile test plates for the assays.
The MDA-MB-231 cells were grown at 37 ◦C in 5% CO2 in Dulbecco’s modified Eagles’s medium
(DMEM high glucose) (Capricorn Scientific) supplemented with 10% fetal bovine serum (Capricorn
Scientific). All of the cells were adherent in monolayers and, upon confluence, were washed with
phosphate buffer saline (PBS) 1× and harvested by digestion with trypsin 0.05% (v/v). Trypsin was
inactivated by adding fresh complete culture media to the culture flask. The cells were then suspended
and transferred into new, sterile, culture flasks, or seeded in sterile test plates for the different assays.
All of the cells were manipulated under aseptic conditions in a flow chamber.
3.4.2. Compounds Dilution and Storage
The compounds were dissolved in DMSO. The aliquots were prepared in sterile conditions and
stored at −20 ◦C, protected from light, and after thawing were discarded. Cisplatin was used as a
positive control and dissolved in a sterile filtered solution of sodium chloride (NaCl) 0.9% (w/v) in
deionized water, stored at −20 ◦C, and protected from light.
3.4.3. Sulforhodamine B (SRB) Assay
The SW480 and NCM460 cells were seeded at a concentration of 1 × 105 cells/ml and 2 × 105
cells/ml, respectively, in 24-well test plates. After 24 h of seeding, the cells were incubated with different
concentrations of the compounds, during 48 h. For each cell line and compound, we performed two
negative controls, a control (1), in which the cells were only incubated with growth medium and
another DMSO control (2), in which the cells were exposed to the concentration of DMSO, in which the
highest concentration of the compound was dissolved (maximum of 0.1% of DMSO per well (v/v)), to
discard any influence of the DMSO in the results. After 48 h of treatment, cells were fixed in ice-cold
methanol containing 1% acetic acid for at least 90 min, at −20 ◦C. The fixing solution was then removed,
and the plate was left air-dry at room temperature. Fixed cells were incubated with 0.5% (w/v) SRB
dissolved in 1% acetic acid for 90 min at 37 ◦C protected from light. After washing with 1% acetic acid
and air-drying at room temperature, SRB was solubilized with 10 mM Tris pH10. Absorbance was
read at 540 nm in a microplate reader (SpectraMax 340PC Molecular Devices, San José, CA, USA). The
results were expressed relative to the negative control 1, which was considered as 100% of cell growth.
The results were obtained from at least three independent experiments, and each experiment was done
in triplicate. The IC50 values were estimated using GraphPad Prism 6 software, while applying a
sigmoidal dose vs response (variable slope) non-linear regression (n = 3). To determine the cytotoxic
selectivity of the substances tested, the selectivity index (SI) was calculated according to the following
equation [38]:
SI = IC50 (normal cell line)/IC50 (cancer cell line) (1)
3.4.4. MTT Assay
The cytotoxicity of the ligands and complexes against the MDA-MB-231 cells was assessed
while using the colorimetric assay MTT (3-(4,5-2-yl)-2,5-ditetrazolium bromide), which measures
the conversion of the yellow tetrazolium into purple formazan by mitochondrial redox activity in
living cells. For this purpose, cells (5 × 103 in 200 µL of medium) were seeded into 96-well plates
and incubated in a 5% CO2 incubator at 37 ◦C. The cells settled for 24 h followed by the addition of
a dilution series of the ligands (1–100 µM) and complexes (2–0.01 µM) in medium (200 µL). DMSO
did not exceed 1%, even for the highest concentration and was without cytotoxic effect. After 48 h
incubation, the treatment solutions were removed by aspiration and MTT solution (200 µL, 0.5 mg/mL
in PBS) was added to each well. After 3–4 h at 37 ◦C/5% CO2, the solution was removed, and the
purple formazan crystals that formed inside the cells were dissolved in DMSO (200 µL) by thorough
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shaking. The cellular viability was evaluated while measuring the absorbance at 570 nm by using a
microplate spectrophotometer.
3.4.5. Colony Formation Assay
The SW480 cell line was seeded, at a concentration of 750 cells/ml, in six-well plates. After 24 h of
seeding, the cells were treated with 14 IC50 and IC50 values of iron and cisplatin compounds. After
48 h, the cells were washed with PBS and the medium was replaced with fresh medium. The negative
control cells were treated with DMSO 0.1%. Eight days later, the cells were washed with PBS and
fixed with glutaraldehyde 6% (v/v) and crystal violet 0.5% (w/v) for three hours. Subsequently, the
cells were washed with fresh water and the plate was left air-dry. Colonies were counted using ImageJ
1.50i software. The results represent mean ± S.D. of at least three independent experiments. Statistical
analysis was performed by one-way ANOVA with Dunnett’s multiple comparisons test. ** P ≤ 0.01;
**** P ≤ 0.0001 as compared with the negative control.
3.4.6. Annexin V/Propidium Iodide Assay
The colorectal cancer-derived cell line SW480 was seeded, in six-well plates, at a concentration of 1
× 105 cells/ml. Twenty-four hours after seeding, the cells were exposed to the IC50 and 2 × IC50 values
of iron compounds and cisplatin. The negative control cells were treated with DMSO 0.1%. After 48 h,
both floating and attached cells were collected and washed with PBS. The cell suspension collected
was centrifuged at 2500 rpm for 10 min and the pellet resuspended in binding buffer. Afterwards, 5 µL
of Annexin V (AV) and 5 µL of Propidium Iodide (PI) at 50 µg/mL were added to each sample and
acquisition was performed using CytoFLEX Cytometer (Beckman Coulter, Brea, CA, USA). The values
represent mean ± S.D. of at least three independent experiments. Statistical analysis was performed by
two-way ANOVA with Dunnett’s multiple comparisons test. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P
≤ 0.0001 when compared with negative control.
3.4.7. F-Actin Staining Assay with Phalloidin 568
SW480 cell line was seeded at a concentration of 1 × 105 cells/ml, in 12-well plates with one
coverslip per well. After 24 h, the cells were exposed to the IC50 values of iron compounds and
cisplatin, and the cells of negative control were treated with DMSO 0.1%. After 48 hours of incubation,
the cells were washed twice with PBS and fixed with paraformaldehyde 4% (w/v) for 10 minutes. After
fixation, cells were incubated with NH4Cl 50 mM and washed twice with PBS, for five minutes. The
cells were permeabilized using Triton X-100 0.2%, for five minutes, and blocked with PBS–BSA 3%
for 20 minutes. Subsequently, cells were incubated with Alexa Fluor™ 568 Phalloidin (ThermoFisher
Scientific®, Waltham, MA, USA), diluted in PBS (1:40), for one hour in the dark, and washed twice
with PBS. To finalize, coverslips were mounted using 5 µL of VECTASHIELD Antifade Mounting
Medium with DAPI (Vector Laboratories®, Peterborough, UK) in microscope slides. The results were
obtained from at least three independent experiments. Representative images were obtained in a
fluorescence microscope (Olympus motorized BX63F Upright Microscope) (Olympus©, Tokyo, Japan)
at a magnification of 600×.
4. Conclusions
In the continuation of our work on the ‘FeCp’ scaffold, a new family of cationic complexes with the
general formula [Fe(η5-C5H5)(CO)(PPh3)(NCR)]+ has been synthesized. All of the compounds were
fully characterized by the usual spectroscopic techniques. X-ray studies for compounds 1, 4, and 5
indicate that they crystalize in the monoclinic space group P21/c and adopt the expected piano-stool
geometry. The DFT studies allowed for a clearer interpretation of the UV-Vis. data, showing that
the low-lying energy transitions are highly mixed, with contributions from d-d, iron to phosphane,
and iron-nitrile ligand to phosphane charge transfers. All of the compounds are cytotoxic in breast
MDA-MB-231 and colorectal SW480 cancer cells with IC50 at a low micromolar range. These compounds
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cause cell death by apoptosis, inhibiting the formation of colonies and affecting cell cytoskeleton
organization. Overall, the biological data revealed that the substituents at the nitrile ligands induce
different biological responses, particularly the hydroxylated compounds (2 and 3) seem to present an
alternative mode of action interfering less with the cytoskeleton of cells.
Supplementary Materials: The following is available online, Figure S1—1H NMR spectrum of complexes 6,
in acetone-d6, Table S1. Bond lengths [Å] and angles [◦] for [Fe(η5-Cp)(CO)(PhCN)(PPh3)][CF3SO3] 1,
[Fe(η5-Cp)(CO)(p-NCPhNH2)(PPh3)][CF3SO3] 4 and [Fe(η5-Cp)(CO)(p-NCPhBr)(PPh3)][CF3SO3] 5, Table S2.
Relevant TD-DFT (PBE0) excitation energies (λ), oscillator strengths (f) and compositions (only those > 5% are
shown), for complexes 1–6, compared with experimental data (λexp). Both calculated and experimental values
were obtained in dichloromethane, Figure S2—UV-Vis spectra of complexes 1–6 in DMSO along the 24 h study,
Figure S3—UV-Vis spectra of complexes 1–6 in DMSO/DMEM mixture along the 24 h study and its variation plot
(%) (bottom), Figure S4. ‘FeCp’ compounds affect the colony formation ability of SW480 cell line. Analysis of
the colony formation ability, after 48 h of incubation with 1/4 IC50 and IC50, in SW480 cell line. Representative
images of colony formation assay in SW480 cell line, Figure S5. ‘FeCp’ compounds induce apoptosis colorectal
cancer-derived cell line. Apoptotic cell death was analyzed by Annexin V fluorescein isothiocyanate (AV-FITC)
and propidium iodide (PI) assay in SW480 cells, after incubation with IC50 and 2×IC50 concentrations for 48 h.
Representative histograms of SW480 cell line double stained with AV and PI, Table S4. Crystal data and structure
refinement for [Fe(η5-Cp)(CO)(PhCN)(PPh3)][CF3SO3] 1, [Fe(η5-Cp)(CO)(p-NCPhNH2)(PPh3)][CF3SO3] 4 and
[Fe(η5-Cp)(CO)(p-NCPhBr)(PPh3)][CF3SO3] 5.
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